Key result
A 67-year-old male suffered in-stent thrombosis after percutaneous coronary intervention, possibly due to a drug-drug interaction between primidone and ticagrelor reducing ticagrelor's efficacy.
Why the study?
Ticagrelor response may be altered by concomitant medications causing subtherapeutic effects, including strong CYP-3A inducers like primidone.
Case Report (n=1)
Concomitant use of primidone and ticagrelor may lead to subtherapeutic ticagrelor levels and subsequent in-stent thrombosis due to CYP-3A induction.
Answers are grounded in this paper and cite their sources.
May warrant reviewing CYP3A inducers like primidone in unexplained ticagrelor failure rather than assuming nonadherence; leaves open confirmation beyond this case.
Ticagrelor and aspirin is a common dual antiplatelet therapy regimen for patients who undergo percutaneous coronary intervention. Despite its ability to significantly reduce cardiovascular complications, ticagrelor response may be altered by other medications causing subtherapeutic effects. Traditionally, ticagrelor is thought to have fewer drug-drug interactions compared to other thienopyridine antiplatelet medications such as clopidogrel. Primidone, metabolized into phenobarbital, is a strong CYP-3A inducer that can reduce serum concentrations of ticagrelor resulting in ineffective antiplatelet therapy. We present a 67-year-old male who suffered in-stent thrombosis after percutaneous intervention possibly due to the interaction between primidone and ticagrelor.
No takes yet. Share an insight, caveat, or question.
Patail et al. (2023) conducted a case report in In-stent thrombosis after percutaneous coronary intervention (n=1). Primidone and ticagrelor interaction was evaluated on In-stent thrombosis. A 67-year-old male suffered in-stent thrombosis after percutaneous coronary intervention, possibly due to a drug-drug interaction between primidone and ticagrelor reducing ticagrelor's efficacy.
Synapse has enriched 10 related papers. Consider them for comparative context: